Cargando…

Counterfeit drugs and medical devices in developing countries

The World Health Organization has reported that counterfeit medicines potentially make up more than 50% of the global drug market, with a significant proportion of these fake products being encountered in developing countries. This occurrence is attributed to a lack of effective regulation and a wea...

Descripción completa

Detalles Bibliográficos
Autor principal: Glass, Beverley D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337201/
https://www.ncbi.nlm.nih.gov/pubmed/32669888
http://dx.doi.org/10.2147/RRTM.S39354
_version_ 1783554463383945216
author Glass, Beverley D
author_facet Glass, Beverley D
author_sort Glass, Beverley D
collection PubMed
description The World Health Organization has reported that counterfeit medicines potentially make up more than 50% of the global drug market, with a significant proportion of these fake products being encountered in developing countries. This occurrence is attributed to a lack of effective regulation and a weak enforcement capacity existing in these countries, with an increase in this trade resulting from the growing size and sophistication of drug counterfeiters. In addition, due to both cost and lack of availability of medicines, consumers in developing countries are more likely to seek out these inexpensive options. The World Health Organization is mindful of the impact of counterfeit drugs on consumer confidence in health care systems, health professionals, the supply chain, and genuine suppliers of medicines and medical devices. Antibiotics, antituberculosis drugs, and antimalarial and antiretroviral drugs are frequently targeted, with reports of 60% of the anti-infective drugs in Asia and Africa containing active pharmaceutical ingredients outside their pharmacopoeial limits. This has obvious public health implications of increasing drug resistance and negating all the efforts that have already gone into the provision of medicines to treat these life threatening conditions in the developing world. This review, while focusing on counterfeit medicines and medical devices in developing countries, will present information on their impact and how these issues can be addressed by regulation and control of the supply chain using technology appropriate to the developing world. The complexity of the problem will also be highlighted in terms of the definition of counterfeit and substandard medicines, including gray pharmaceuticals. Although this issue presents as a global public health problem, outcomes in developing countries where counterfeit drugs to treat malaria, tuberculosis, and human immunodeficiency virus/acquired immunodeficiency syndrome not only result in drug resistance, but a number of deaths from the untreated disease, is in stark contrast with the developed world, where lifestyle drugs such as sildenafil (Viagra(®)) are most commonly counterfeited.
format Online
Article
Text
id pubmed-7337201
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-73372012020-07-14 Counterfeit drugs and medical devices in developing countries Glass, Beverley D Res Rep Trop Med Review The World Health Organization has reported that counterfeit medicines potentially make up more than 50% of the global drug market, with a significant proportion of these fake products being encountered in developing countries. This occurrence is attributed to a lack of effective regulation and a weak enforcement capacity existing in these countries, with an increase in this trade resulting from the growing size and sophistication of drug counterfeiters. In addition, due to both cost and lack of availability of medicines, consumers in developing countries are more likely to seek out these inexpensive options. The World Health Organization is mindful of the impact of counterfeit drugs on consumer confidence in health care systems, health professionals, the supply chain, and genuine suppliers of medicines and medical devices. Antibiotics, antituberculosis drugs, and antimalarial and antiretroviral drugs are frequently targeted, with reports of 60% of the anti-infective drugs in Asia and Africa containing active pharmaceutical ingredients outside their pharmacopoeial limits. This has obvious public health implications of increasing drug resistance and negating all the efforts that have already gone into the provision of medicines to treat these life threatening conditions in the developing world. This review, while focusing on counterfeit medicines and medical devices in developing countries, will present information on their impact and how these issues can be addressed by regulation and control of the supply chain using technology appropriate to the developing world. The complexity of the problem will also be highlighted in terms of the definition of counterfeit and substandard medicines, including gray pharmaceuticals. Although this issue presents as a global public health problem, outcomes in developing countries where counterfeit drugs to treat malaria, tuberculosis, and human immunodeficiency virus/acquired immunodeficiency syndrome not only result in drug resistance, but a number of deaths from the untreated disease, is in stark contrast with the developed world, where lifestyle drugs such as sildenafil (Viagra(®)) are most commonly counterfeited. Dove 2014-04-24 /pmc/articles/PMC7337201/ /pubmed/32669888 http://dx.doi.org/10.2147/RRTM.S39354 Text en © 2014 Glass http://creativecommons.org/licenses/by-nc/3.0/ This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
spellingShingle Review
Glass, Beverley D
Counterfeit drugs and medical devices in developing countries
title Counterfeit drugs and medical devices in developing countries
title_full Counterfeit drugs and medical devices in developing countries
title_fullStr Counterfeit drugs and medical devices in developing countries
title_full_unstemmed Counterfeit drugs and medical devices in developing countries
title_short Counterfeit drugs and medical devices in developing countries
title_sort counterfeit drugs and medical devices in developing countries
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337201/
https://www.ncbi.nlm.nih.gov/pubmed/32669888
http://dx.doi.org/10.2147/RRTM.S39354
work_keys_str_mv AT glassbeverleyd counterfeitdrugsandmedicaldevicesindevelopingcountries